DermWire | Newest Articles http://practicaldermatology.com/dermwire/ Newest Articles en-us Mon, 26 Jun 2017 03:26:09 GMT Mon, 26 Jun 2017 03:26:09 GMT DermWire Dysport Approved for Lower Limb Spasticity http://practicaldermatology.com/dermwire/view.asp?url=dysport-approved-for-lower-limb-spasticity The FDA has expanded the indication of Dysport (abobotulinumtoxinA, Ipsen Biopharmaceuticals) to include lower limb spasticity. In a Phase 3 study, adult patients treated with Dysport following a stroke or traumatic brain injury showed improvement in muscle tone at the ankle joint at four weeks. The duration of response for the majority of patients was between 12 to 16 weeks, while some patients experienced response for as long as 20 weeks. Repeat Dysport treatment should be administered when… Thu, 22 Jun 2017 04:00:00 GMT Phase 3 Results Published for Investigational Levodopa-Induced Dyskinesia Treatment http://practicaldermatology.com/dermwire/view.asp?url=phase-3-results-published-for-investigational-levodopa-induced-dyskinesia-treatment Results from the Phase 3 EASE LID clinical trial, published online in JAMA Neurology, show that the investigational ADS-5102 (amantadine, Adamas Pharmaceuticals) reduces levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). In the randomized, double-blind, placebo-controlled study, patients who received ADS-5102 experienced a significantly greater decrease in LID at 12 weeks than those who received placebo, as measured by the Unified Dyskinesia Rating Scale (UDysR… Wed, 14 Jun 2017 04:00:00 GMT AHS 2017: Amgen’s CGRP Inhibitor Reduces Migraine Days http://practicaldermatology.com/dermwire/view.asp?url=amgen-unveils-positive-phase-2-data-for-cgrp-inhibitor New Phase 2 data show that Amgen’s investigational investigational CGRP inhibitor erenumab is effective at preventing migraine in patients experiencing 15 or more migraine days per month. In a study presented at the recent American Headache Society Annual Meeting in Boston, patients treated with erenumab experienced a reduction in monthly migraine days by 6.6, as compared to a 3.5-day reduction in placebo. In addition, days requiring acute pain-relief medications were also significantly re… Tue, 13 Jun 2017 04:00:00 GMT American Epilepsy Society Awards Investigators for Early Career Research http://practicaldermatology.com/dermwire/view.asp?url=american-epilepsy-society-awards-investigators-for-early-career-research The American Epilepsy Society (AES) has awarded 25 early career scientists and clinicians with fellowships or grants to support their work in epilepsy research. The award recipients include pre-doctoral and post-doctoral trainees, junior investigators establishing their independent programs, and clinicians and fellows pursuing additional training for a career in research. As part of the AES’s commitment to support those starting their careers in epilepsy research, the number of fel… Mon, 12 Jun 2017 04:00:00 GMT Anti-Alpha-Synuclein Antibody Shows Early Potential as Parkinson’s DMT http://practicaldermatology.com/dermwire/view.asp?url=anti-alpha-synuclein-antibody-shows-early-potential-as-parkinsons-dmt PRX002, an investigational monoclonal antibody, may inhibit cell-to-cell transmission of alpha-synuclein and modify disease progression in Parkinson’s disease (PD), according to a study presented at the recent International Congress of Parkinson’s Disease and Movement Disorders in Vancouver. Researchers evaluated the use of PRX002 in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. The patient population consisted of 80 predominantly Caucasian males with mi… Fri, 9 Jun 2017 04:00:00 GMT AHS 2017 Meeting: Prochlorperazine More Effective than Hydromorphone for Acute Migraine http://practicaldermatology.com/dermwire/view.asp?url=ahs-2017-meeting-prochlorperazine-more-effective-than-the-opioid-hydromorphone-for-acute-migraine A new comparative study presented at the American Headache Society Annual Meeting in Boston shows that that, in patients who visit the emergency department for acute migraine treatment, prochorperazine is more effective than the opioid drug, hydromorphone. The randomized, double-blind, comparative study was conducted in two emergency departments (EDs) in New York City. Qualifying patients visiting the ED for acute migraine treatment were assigned to receive prochlorperazine 10 mg plus diphenhydr… Thu, 8 Jun 2017 04:00:00 GMT AHS 2017 Meeting: Non-Invasive Medical Devices Show Promise for Severe Headaches http://practicaldermatology.com/dermwire/view.asp?url=ahs-2017-meeting-non-invasive-medical-devices-show-promise-for-severe-headaches Results from studies presented at the American Headache Society Annual Meeting in Boston suggest that non-invasive medical devices offer effective interventions for individuals with migraine. New findings from a randomized, placebo-controlled study showing that non-invasive caloric vestibular stimulation (nCVS) can prevent episodic migraine. The vestibular organs comprise the sensory system within the inner ear and provide balance control and spatial orientation. Patients who used the nCVS de… Thu, 8 Jun 2017 04:00:00 GMT Smartphone Sensor Data Offer Insights Into Daily Functioning in Patients with Parkinson’s Disease http://practicaldermatology.com/dermwire/view.asp?url=smartphone-sensor-data-offer-insights-into-daily-functioning-in-patients-with-parkinsons-disease Smartphones are a valuable resource in gaining mobility data in patients with Parkinson’s disease, according to new research presented at the 21st International Congress of Parkinson’s Disease and Movement Disorders (Abstract 541). Evaluating 44 PD patients in a home-based setting using smartphone-based assessments over a 24-week period, investigators categorized data into different types of human activities and compared to the study’s clinical data. In over 25,000 hours of pas… Wed, 7 Jun 2017 04:00:00 GMT Teva’s Fremanezumab Reduces Monthly Headache Days in Phase 3 Chronic Migraine Study http://practicaldermatology.com/dermwire/view.asp?url=tevas-fremanezumab-reduces-monthly-headache-days-in-phase-3-chronic-migraine-study Results from the Phase 3 HALO study suggest that fremanezumab (Teva Pharmaceuticals) reduces the number of monthly headache days in patients with chronic migraine. Fremanezumab is a fully-humanized monoclonal antibody targeting the CGRP ligand. In the study, patients treated with fremanezumab experienced statistically significant reduction in the number of monthly headache days of at least moderate severity vs. placebo (-2.5 days) during the 12-week period after first dose, for both mon… Thu, 1 Jun 2017 04:00:00 GMT Neurodegenerative Diseases Linked by Abnormal Proteins Causing Similar Damage to Brain Cells http://practicaldermatology.com/dermwire/view.asp?url=neurodegenerative-diseases-linked-by-abnormal-proteins-causing-similar-damage-to-brain-cells Abnormal proteins found in Alzheimer's disease, Parkinson's disease, and Huntington's disease share a similar ability to cause damage when they invade brain cells, according to recently published findings (Acta Neuropathol, May 19, 2017). Investigators monitored amyloid assemblies in α-synuclein (α-syn), tau, and huntingtin Exon1 with pathologic polyglutamine repeats and found that they had a similar ability to induce intracellular vesicle rupture. While more research is … Tue, 30 May 2017 04:00:00 GMT NEJM Publishes Phase 3 Data for Epidiolex in Dravet Syndrome as Manufacturer Eyes Mid-2017 NDA Submission http://practicaldermatology.com/dermwire/view.asp?url=nejm-publishes-phase-3-data-for-epidiolex-in-dravet-syndrome-as-manufacturer-eyes-mid-2017-nda-submission The New England Journal of Medicine has published results from a Phase 3 study showing that Epidiolex (cannabidiol, GW Pharmaceuticals) reduces monthly convulsive seizure frequency compared to placebo in children with Dravet syndrome. The study randomized 120 children ages two to 18 years with Dravet syndrome whose seizures were not controlled by their current anti-epileptic regimen, to receive either Epidiolex (20mg/kg/day) or placebo in addition to standard treatment. Patients in the study had… Fri, 26 May 2017 04:00:00 GMT Celgene’s Investigational MS Agent Reduces Annual Relapse Rate but Falls Short of Disability Endpoint in Phase 3 Trial http://practicaldermatology.com/dermwire/view.asp?url=celgenes-investigational-ms-agent-reduces-annual-relapse-rate-but-falls-short-of-disability-endpoint-in-phase-3-trial New Phase 3 findings suggest that Celgene’s investigational ozanimod for relapsing multiple sclerosis (MS) reduces annualized relapse rate in a clinically meaningful way but does not significantly impact disease disability. In the RADIANCE trial, 1,313 patients with relapsing MS were randomized to receive either 0.5 mg or 1 mg of ozanimod, a sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, or weekly interferon beta-1a (Avonex), over a two-year period. Both doses of ozani… Tue, 23 May 2017 04:00:00 GMT Migraine Prevalence Higher in Collegiate Athletes, New Study Finds http://practicaldermatology.com/dermwire/view.asp?url=migraine-prevalence-higher-in-collegiate-athletes-new-study-finds New findings suggest that collegiate athletes have an increased prevalence of migraines, with female athletes being particularly affected. In a retrospective cross-section survey, researchers evaluated 834 student athletes from NCAA Division-I institutions (Headache, May 7, 2017. The sample included athletes in a variety of sports with differing degrees of contact exposure. The survey consisted of 20 questions pertaining to personal and family history of head, as well as a concussion history. Fi… Fri, 19 May 2017 04:00:00 GMT Endovascular Intervention Found Effective for "Late Window" Stroke Patients: DAWN Trial Analysis http://practicaldermatology.com/dermwire/view.asp?url=endovascular-intervention-found-effective-for-late-window-stroke-patients-dawn-trial-analysis The window for reducing disability and improving functional independence in stroke patients receiving endovascular therapy could extend as far as 24 hours, according to preliminary results from the DAWN trial presented at the European Stroke Organization Conference (ESOC). Assessing late-window and wake-up stroke patients, investigators found that treatment with the Trevo Retriever (Stryker) significantly decreased post-stroke and improved functional independence at 90 days when compared to medi… Tue, 16 May 2017 04:00:00 GMT Endovascular Intervention Found Effective for “Late Window” Stroke Patients: DAWN Trial Analysis http://practicaldermatology.com/dermwire/view.asp?url=endovascular-intervention-found-effective-for-late-window-stroke-patients-dawn-trial-analysis The window for reducing disability and improving functional independence in stroke patients receiving endovascular therapy could extend as far as 24 hours, according to preliminary results from the DAWN trial presented at the European Stroke Organization Conference (ESOC). Assessing late-window and wake-up stroke patients, investigators found that treatment with the Trevo Retriever (Stryker) significantly decreased post-stroke and improved functional independence at 90 days when compared to medi… Tue, 16 May 2017 04:00:00 GMT Elevated B2M Levels Tied to Ischemic Stroke Risk in Women http://practicaldermatology.com/dermwire/view.asp?url=elevated-b2m-levels-tied-to-ischemic-stroke-risk-in-women β2-microglobulin (B2M) levels may be an indicator of ischemic stroke risk in women, according to new findings published in Neurology (May 10). Investigators performed a nested case-control study among women enrolled in the Nurses' Health Study who provided blood samples between 1989 and 1990 and were free of prior stroke and cancer. They analyzed the association between B2M and ischemic stroke using multivariable conditional logistic regression to adjust for traditional stroke risk fact… Fri, 12 May 2017 04:00:00 GMT Lilly’s Investigational Monoclonal Antibody for Migraine Scores Positive Phase 3 Results http://practicaldermatology.com/dermwire/view.asp?url=lillys-investigational-monoclonal-antibody-for-migraine-scores-positive-phase-3-results New Phase 3 data suggest that Eli Lilly’s investigational monoclonal antibody galcanezumab may significantly reduce the number of monthly migraine headache days. In the EVOLVE-1 study, patients with episodic migraine treated with galcanezumab 120 mg over a six-month period experienced an average reduction of 4.7 monthly migraine days, while patients receiving 240 mg experienced an average reduction of 4.6 days, compared to an average reduction of 2.8 days for placebo. In the similarly desi… Fri, 12 May 2017 04:00:00 GMT Special Report—Expanding the Scope of Neurology: An Interview with Ralph L. Sacco, MD http://practicaldermatology.com/dermwire/view.asp?url=special-reportexpanding-the-scope-of-neurology-an-interview-with-ralph-l-sacco-md Following are exerpts from Practical Neurology® magazine's interview with AAN President Ralph L. Sacco, MD. See the upcoming May edition for the full interview. When Ralph L. Sacco, MD, MS, FAHA, FAAN, assumed the role as President of the American Academy of Neurology (AAN) at the recent AAN Annual Meeting in Boston, he had both a clear vision for the future of neurology and a plan for how to get there. “It’s all about teamwork and collaboration across organizations and na… Mon, 8 May 2017 04:00:00 GMT FDA Greenlights First New Treatment for ALS in More than Two Decades http://practicaldermatology.com/dermwire/view.asp?url=fda-greenlights-first-new-treatment-for-als-in-more-than-two-decades The FDA has approved Radicava (edaravone, MT Pharma), as an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS). Radicava is the first treatment approved for the treatment of ALS in 22 years. The approval followed a 13-year comprehensive clinical development program, in which a pivotal Phase 3 study (MCI186-19) evaluating 137 people with ALS demonstrated that patients who received Radicava for six months experienced roughly 33 percent less decline in physical function than tho… Fri, 5 May 2017 04:00:00 GMT MS Topography App Launches http://practicaldermatology.com/dermwire/view.asp?url=ms-topography-app-now-available A new app that offers a new, visual way of understanding multiple sclerosis (MS) was recently launched at the American Academy of Neurology Annual Meeting in Boston. The app is a disease simulation that creates visualization of MS as a swimming pool. According to creator and MS specialist Stephen C. Krieger, MD, the app depicts an MS disease topography, mapped in the central nervous stem, as a tool to better understand the variable way MS can develop and change over time. “We have categori… Thu, 4 May 2017 04:00:00 GMT New Data Highlight Efficacy and Safety of Brain Responsive Neuromodulation for Reduction of Seizures http://practicaldermatology.com/dermwire/view.asp?url=seven-year-data-highlight-efficacy-and-safety-of-brain-responsive-neuromodulation-for-reduction-of-seizures Two new studies offer long-term perspective on the efficacy and safety of brain responsive neuromodulation for the reduction of seizures. One study evaluated the effects of NeuroPace’s RNS System in patients with medically intractable mesial temporal lobe epilepsy (Epilepsia. 2017 Apr 11), while the other looked at its effects on patients with medically intractable seizures arising from eloquent and other neocortical areas (Epilepsia. 2017 Apr 7). In the latter study, the median reduction … Wed, 3 May 2017 04:00:00 GMT Ralph Sacco Begins Two-Year Term as AAN President http://practicaldermatology.com/dermwire/view.asp?url=ralph-sacco-begins-two-year-term-as-aan-president Ralph L. Sacco, MD has assumed the role president of the American Academy of Neurology (AAN). Dr. Sacco is Professor and Chair of the Neurology department at the Miller School of Medicine at the University of Miami. He succeeds Terrence L. Cascino, MD, who completed his two-year term as president during the recent AAN Annual Meeting in Boston. Sacco is a career-long member of the AAN and was the first neurologist to serve as the president of the American Heart Association from 2010 to 2011. H… Mon, 1 May 2017 04:00:00 GMT AAN 2017 Meeting: Racial and Regional Disparities Identified in Endovascular Care Delivery http://practicaldermatology.com/dermwire/view.asp?url=aan-2017-meeting-racial-and-regional-disparities-identified-endovascular-care-delivery Access to endovascular care is significantly impacted by factors such as race, region, and hospital, according to findings presented this week at the American Academy of Neurology (AAN) Annual Meeting in Boston. Investigators analyzed data from a large registry to determine use of endovascular therapy in ischemic stroke patients. Among more than 58,000 patients in Florida and Puerto Rico, 3.6 percent received thrombectomy. Compared to those patients not treated with endovascular therapy, patient… Fri, 28 Apr 2017 04:00:00 GMT AAN 2017 Meeting: New Data Reinforce Efficacy of Ocrelizumab http://practicaldermatology.com/dermwire/view.asp?url=aan-2017-new-data-reinforce-efficacy-of-ocrelizumab New data presented at the American Academy of Neurology (AAN) Annual Meeting in Boston show the benefits of ocrelizumab in relapsing multiple sclerosis (MS). In a pooled analysis of Phase 3 OPERA studies, ocrelizumab reduced the relapse rate by 55 percent compared to interferon beta-1a. Additional analyses of the OPERA studies showed the efficacy of ocrelizumab in people with early relapsing MS, suppressing more than 90 percent of active MRI lesions over two years compared with interferon beta-1… Wed, 26 Apr 2017 04:00:00 GMT AAN 2017 Meeting: New Evidence Suggest Parkinson’s Originates in the Gut http://practicaldermatology.com/dermwire/view.asp?url=aan-2017-meeting-new-evidence-suggest-parkinsons-originates-in-the-gut Parkinson’s disease may start in the gut and spread to the brain via the vagus nerve, according to a study published in the April 26, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology. When researchers analyzed the results from preliminary research for the two different types of vagotomy surgery, they found that people who had a truncal vagotomy at least five years earlier were less likely to develop Parkinson’s disease than those who had … Wed, 26 Apr 2017 04:00:00 GMT